Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco (NYSE: ELAN) reported Q4 2025 revenue of $1,144M (+12% reported, +9% organic CC) and full-year 2025 revenue of $4,715M (+6% reported, +7% organic CC). Innovation revenue exceeded target at $892M and 2026 innovation target raised to $1.15B. Reported net loss was $276M in Q4 and $232M for 2025; adjusted EBITDA was $189M Q4 and $901M FY. Full-year 2026 guidance: revenue $4,950–$5,020M, adjusted EBITDA $955–$985M, adjusted EPS $1.00–$1.06, and year-end net leverage target 3.1x–3.3x.
Elanco (NYSE: ELAN) announced management participation in multiple investor conferences between Feb 26 and Mar 17, 2026. Executives including Jeff Simmons, Bob VanHimbergen, Luke Smith and Bobby Modi will appear in scheduled fireside chats with banks and healthcare conferences.
Live audio webcasts will be available in the Events and Presentations section of Elanco's investor website; replays will be posted for a limited time after each event.
Elanco (NYSE: ELAN) announced on Feb 13, 2026 that R. David Hoover and Deborah Kochevar will not stand for re-election at the 2026 Annual Meeting in May. Hoover is retiring after joining the board in Sept 2018 as founding chairman; Kochevar joined in March 2019.
The company said Hoover helped guide the spin-off and early public years, and Kochevar chaired the Innovation, Science and Technology committee. Following these departures, the board will consist of nine directors.
Elanco (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A conference call with the investment community and media will be held the same day starting at 8:00 a.m. Eastern Standard Time. Investors, media, and the public can access a live webcast via Elanco's investor website and a replay will be available on the site shortly after the call.
Elanco (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 p.m. EST).
A live audio webcast will be available in the Events and Presentations section of Elanco's investor website, and a replay will be available for a limited time after the event.
Elanco (NYSE: ELAN) received USDA approval for Befrena (tirnovetmab), an anti‑IL31 monoclonal antibody injection for canine allergic and atopic dermatitis, recommended at a 6–8 week dosing interval. Befrena is approved for dogs of any age and is expected to launch in the first half of 2026. This marks Elanco's second dermatology approval in under 18 months and positions the product in the estimated $1.3 billion U.S. canine dermatology market. The approval complements Elanco's Zenrelia oral JAK inhibitor franchise; Zenrelia's label retains a boxed warning advising discontinuation for 28 days to 3 months around vaccination.
Elanco (NYSE: ELAN) announced FDA conditional approval of Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, pyrantel) for treatment of New World screwworm larvae in dogs on Dec 18, 2025. This is the first FDA conditional approval for a companion-animal product for screwworm and joins Credelio and Credelio CAT as treatment options. A peer‑reviewed study reported oral lotilaner at the minimum dose achieved 100% efficacy within 24 hours in naturally infested dogs. Product labeling reflecting conditions of use will appear in 2026. Credelio Quattro now provides 7-in-1 parasite coverage including screwworm.
Elanco (NYSE: ELAN) held Investor Day on Dec 9, 2025, outlining a three-year plan that targets sustainable growth beginning in 2026. Key financial targets include mid-single digit organic revenue growth, high-single digit adjusted EBITDA growth, low-double digit adjusted EPS growth, and at least $1B free cash flow from 2026–2028. The company expects net leverage <3.0x in 2027 with a long-term target of 2.0x–2.5x and forecasts ~$1.1B innovation revenue in 2026.
Operational moves: closure of a German R&D facility, U.S. R&D and manufacturing investments, an accelerated USDA conditional pathway for a potential immuno-therapeutic, and Befrena administrative review with an expected H1 2026 launch. Elanco announced an Elanco Ascend restructuring: ~$175M charge, ~$130M cash, ~600 roles impacted, and expected savings of $200–$250M by 2030.
Neurizon Therapeutics announced on 26 November 2025 that Justine Conway, Global Head of Business Development at Elanco (NYSE: ELAN), has been appointed as an Elanco-designated Board Observer. The appointment follows an exclusive global license agreement for Monepantel (active ingredient in NUZ-001) dated 2 July 2025, and is intended to reinforce Neurizon's regulatory foundations by providing ongoing access to animal safety and manufacturing data needed for future trials and approvals.
Ms Conway brings more than 20 years of healthcare and animal health business development experience. As Board Observer she may attend and participate in board and committee meetings but will not hold voting rights. The company said her expertise will support advancement of NUZ-001 toward late-stage development and planned entry into the HEALEY ALS Platform Trial this quarter.
Elanco (NYSE: ELAN) announced that on Nov 21, 2025 the U.S. Food and Drug Administration granted an Emergency Use Authorization (EUA) for Credelio CAT (lotilaner) to treat New World screwworm (NWS) in cats.
This is the first FDA EUA for NWS treatment in felines and follows a prior EUA for Credelio in dogs. The authorization is based on studies showing potential efficacy (Old World screwworm data in cats and New World data in dogs) and aims to provide a ready treatment option as confirmed NWS cases have been detected within ~70 miles south of the U.S.-Mexico border.